No, bridging is NOT needed for patients on Eliquis (apixaban) undergoing orthopedic surgery.
The rapid offset and onset of action of direct oral anticoagulants (DOACs) like Eliquis eliminate the need for perioperative heparin bridging. 1
Why Bridging is Not Required
DOACs have fundamentally different pharmacokinetics compared to warfarin:
This means the drug clears predictably and rapidly without the need for bridging anticoagulation.
Evidence Against Bridging with DOACs
Multiple studies demonstrate that perioperative LMWH bridging with DOACs increases major bleeding risk without reducing thromboembolism:
- Bridging was associated with threefold higher major bleeding (4.8% vs 1.6%) with no difference in stroke/systemic embolism rates 1
- In the RE-LY subanalysis, bridging increased major bleeding (6.5% vs 1.8%; P < .001) without reducing thrombotic events 1
- A prospective registry showed bridging increased major bleeding risk (OR 4.6) without thromboembolic benefit 1
Perioperative Management Algorithm for Eliquis
Pre-operative Interruption:
For high-bleed-risk orthopedic surgery (which most orthopedic procedures are):
- Stop Eliquis 48 hours before surgery 3
- This allows 4-5 drug half-lives for complete clearance
- No bridging anticoagulation needed 1, 3
For low-to-moderate-bleed-risk procedures:
- Stop Eliquis 24 hours before surgery 1
Post-operative Resumption:
After high-bleed-risk orthopedic surgery:
- Resume Eliquis 48-72 hours post-operatively once adequate hemostasis is achieved 1
- The FDA label states to restart "as soon as adequate hemostasis has been established" 3
After low-to-moderate-bleed-risk procedures:
- Resume at least 24 hours post-operatively 1
Important Caveats
VTE Prophylaxis vs. Bridging
Do not confuse standard post-operative VTE prophylaxis with bridging:
- Low-dose LMWH (e.g., enoxaparin 40 mg daily) for VTE prophylaxis after major orthopedic surgery is appropriate and recommended 1
- This is NOT the same as therapeutic-dose bridging (e.g., enoxaparin 1 mg/kg BID), which is not indicated 1
Special Consideration for History of PE
The patient's history of PE does not change this recommendation. The indication for their chronic anticoagulation (whether PE, atrial fibrillation, or other) does not affect the perioperative management strategy for DOACs 1. The rapid pharmacokinetics of apixaban make bridging unnecessary regardless of the underlying thrombotic risk.
Mechanical Heart Valves Exception
The only scenario where DOACs should not be used (and therefore this guidance doesn't apply) is in patients with mechanical heart valves 2, 3. These patients require warfarin with potential bridging considerations.
Common Pitfall to Avoid
Do not apply warfarin bridging protocols to DOAC patients. The 2024 AHA/ACC guidelines and 2022 CHEST guidelines explicitly state that bridging is generally limited to very high-risk patients on warfarin (e.g., mechanical mitral valves), not DOAC patients 2, 1. The evidence shows bridging DOACs causes harm without benefit 1, 4.